BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P, Launay O. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect 2021:S1198-743X(21)00566-8. [PMID: 35020589 DOI: 10.1016/j.cmi.2021.09.036] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 24.0] [Reference Citation Analysis]
Number Citing Articles
1 Chikileva I, Shubina I, Burtseva A, Kirgizov K, Stepanyan N, Varfolomeeva S, Kiselevskiy M. Antiviral Cell Products against COVID-19: Learning Lessons from Previous Research in Anti-Infective Cell-Based Agents. Biomedicines 2022;10:868. [DOI: 10.3390/biomedicines10040868] [Reference Citation Analysis]
2 Jacobsen H, Sitaras I, Jurgensmeyer M, Mulders MN, Goldblatt D, Feikin DR, Bar-Zeev N, Higdon MM, Knoll MD. Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera. Vaccines (Basel) 2022;10:850. [PMID: 35746460 DOI: 10.3390/vaccines10060850] [Reference Citation Analysis]
3 Rabinowitz KM, Navon M, Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Aharoni Golan M, Shachar E, Ben-Horin S, Maharshak N, Mor M, Ben Zvi H, Eliakim R, Barkan R, Sharar-Fischler T, Goren S, Krugliak N, Pichinuk E, Mor M, Werbner M, Alter J, Abu-Taha H, Kaboub K, Dessau M, Gal-Tanamy M, Cohen D, Freund NT, Dotan I, On Behalf Of The Responses To Covid-Vaccine Israeli Ibd. Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. Vaccines (Basel) 2022;10:1186. [PMID: 35893835 DOI: 10.3390/vaccines10081186] [Reference Citation Analysis]
4 Golshani M, Hrdý J. Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination. Vaccines 2022;10:279. [DOI: 10.3390/vaccines10020279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Rodríguez-Cubillo B, Moreno de la Higuera MA, Pérez-Flores I, Calvo Romero N, Aiffil AS, Arribi Vilela A, Peix B, Huertas S, Juez A, Sanchez-Fructuoso AI. Clinical Effectiveness of SARS-CoV-2 Vaccination in Renal Transplant Recipients. Antibody Levels Impact in Pneumonia and Death. Transplantation 2022. [PMID: 35859270 DOI: 10.1097/TP.0000000000004261] [Reference Citation Analysis]
6 Wong G, Rowlandson M, Sabanayagam D, Ginn AN, Kable K, Sciberras F, Au E, Draper J, Arnott A, Sintchenko V, Dwyer DE, Chen SCA, Kok J. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes. Transplantation 2022. [PMID: 35675438 DOI: 10.1097/TP.0000000000004203] [Reference Citation Analysis]
7 Mazonakis N, Tsioutis C, Markaki I, Papadakis M, Papadakos S, Spernovasilis N. Coronavirus disease 2019 (COVID-19) oral antivirals stewardship: Establishing game rules. Infect Control Hosp Epidemiol 2022;:1-2. [PMID: 35115067 DOI: 10.1017/ice.2022.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liew ZH, Leeu JJ, Tan HZ, Mok IYJ, Choo JCJ, Lim CC. COVID-19 vaccine acceptance among patients with glomerulonephritis. Nephrology (Carlton) 2022. [PMID: 35114736 DOI: 10.1111/nep.14026] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Green NS, Van Doren L, Licursi M, Billings DD, Sandoval LA, Feit YMZ, Hod EA. Anti-SARS-CoV-19 antibodies in children and adults with sickle cell disease: A single-site analysis in New York City. Br J Haematol 2022. [PMID: 35759223 DOI: 10.1111/bjh.18294] [Reference Citation Analysis]
10 Pellicano C, Campagna R, Oliva A, Leodori G, Miglionico M, Colalillo A, Mezzaroma I, Mastroianni CM, Turriziani O, Rosato E. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis. Clin Rheumatol 2022. [PMID: 35614287 DOI: 10.1007/s10067-022-06219-7] [Reference Citation Analysis]
11 Moss P, Berenbaum F, Curigliano G, Grupper A, Berg T, Pather S. Benefit–Risk Evaluation of COVID-19 Vaccination in Special Population Groups of Interest. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.05.067] [Reference Citation Analysis]
12 Jahn M, Korth J, Dorsch O, Anastasiou OE, Krawczyk A, Brochhagen L, van de Sand L, Sorge-hädicke B, Tyczynski B, Witzke O, Dittmer U, Dolff S, Wilde B, Kribben A. Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis. Vaccines 2022;10:327. [DOI: 10.3390/vaccines10020327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 See KC. Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews. Vaccines 2022;10:800. [DOI: 10.3390/vaccines10050800] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper. J Hepatol 2022:S0168-8278(22)02942-7. [PMID: 35868584 DOI: 10.1016/j.jhep.2022.07.008] [Reference Citation Analysis]
15 Miele M, Busà R, Russelli G, Sorrentino MC, Di Bella M, Timoneri F, Vitale G, Calzolari E, Vitulo P, Mularoni A, Conaldi PG, Bulati M. Analysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 Infection. Microorganisms 2022;10:1563. [DOI: 10.3390/microorganisms10081563] [Reference Citation Analysis]
16 Vinson AJ, Anzalone AJ, Sun J, Dai R, Agarwal G, Lee SB, French E, Olex A, Ison MG, Mannon RB; N3C consortium. The risk and consequences of breakthrough SARS-CoV-2 infection in solid organ transplant recipients relative to non-immunosuppressed controls. Am J Transplant 2022. [PMID: 35674237 DOI: 10.1111/ajt.17117] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]